Gilead Sciences, Inc. (FRA:GIS)
107.74
-0.62 (-0.57%)
At close: Dec 1, 2025
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
€1,408,571
Profits / Employee
€392,736
Market Cap
132.69B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 1,800 | 15.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Gilead Sciences News
- 6 days ago - Gilead Sciences: About To Break Out - Seeking Alpha
- 7 days ago - Gilead Foundation Commits Over $3 Million to Address Food Insecurity - Business Wire
- 11 days ago - Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength - Seeking Alpha
- 11 days ago - $100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield - Seeking Alpha
- 11 days ago - $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today - Benzinga
- 11 days ago - MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC - Nasdaq
- 11 days ago - Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Nasdaq
- 11 days ago - Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs - PRNewsWire